Phosphoric acid

Identification

Summary

Phosphoric acid is an ingredient used for electrolyte replenishment and total parenteral nutrition (TPN) therapy, and for the relief of upset stomach associated with nausea.

Brand Names
Freamine III 10, Hepatamine 8, Procalamine 3
Generic Name
Phosphoric acid
DrugBank Accession Number
DB09394
Background

Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 97.9952
Monoisotopic: 97.976895096
Chemical Formula
H3O4P
Synonyms
Not Available
External IDs
  • E 338
  • E-338
  • FEMA NO. 2900
  • INS NO.338
  • INS-338
  • NSC-80804
  • Y-11A06

Pharmacology

Indication

Phosphoric acid is used in dentistry and orthodontics as an etching solution, to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport.

Mechanism of action

Phosphate supplementation of the diet of rodents has been shown to lead to reduction in the incidence of dental caries and different phosphates have different powers in reducing the cariogenic potential of the carbohydrates in a diet. Phosphate supplements seem to exert their cariostatic effect on the tooth surface either directly during eating or by excretion in the saliva.

Absorption

Ortho phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract.

Volume of distribution

Absorbed phosphoric acid is distributed widely in the body as phosphate. Increased serum phosphate concentrations have been reported rarely after phosphoric acid ingestion

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine.

Half-life

In infants with normal renal function the serum half-life of phosphate following single oral or rectal overdose is 5-11 hours

Clearance

Absorbed phosphate is filtered at the glomerulus and partially reabsorbed, with phosphate clearance 80 per cent of creatinine clearance.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Man: LDLo, route unreported at 220mg/kg Rabbit: LD 50, Route: Skin, Reported dose: 2740 mg /kg, Effects: Behavioral : somnolence ( general depressed activity), Excitement Rat: LC50, Route: inhalation, Reported dose: >850 mg/m3/1h Rat: LD50, Route: oral, Reported dose: 1530 mg/kg, Effects: Kidney, ureter and bladder hematuria, Behavioral: somnolence (general depressed activity)

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Phosphoric acid which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AminosynPhosphoric acid (40 mg/100mL) + Alanine (448 mg/100mL) + Arginine (343 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (252 mg/100mL) + Leucine (329 mg/100mL) + Lysine acetate (252 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phenylalanine (154 mg/100mL) + Potassium acetate (128 mg/100mL) + Proline (300 mg/100mL) + Serine (147 mg/100mL) + Sodium chloride (234 mg/100mL) + Threonine (182 mg/100mL) + Tryptophan (56 mg/100mL) + Tyrosine (31 mg/100mL) + Valine (280 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-232017-11-01US flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralCardinal Health2020-07-27Not applicableUS flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + D-glucose monohydrate (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralMedicine Shoppe International2008-02-062013-06-09US flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralH.E.B.1995-11-222017-09-08US flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralRite Aid1996-06-122017-11-04US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralRite Aid1996-06-122017-11-04US flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + D-glucose monohydrate (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralMedicine Shoppe International2008-02-062013-06-09US flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralRUGBY LABORATORIES2020-09-09Not applicableUS flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralH.E.B.1995-11-222017-09-08US flag
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralKroger2000-10-042017-11-01US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Non-metal oxoanionic compounds
Sub Class
Non-metal phosphates
Direct Parent
Non-metal phosphates
Alternative Parents
Inorganic oxides
Substituents
Inorganic oxide / Non-metal phosphate
Molecular Framework
Not Available
External Descriptors
phosphoric acids (CHEBI:26078)
Affected organisms
Not Available

Chemical Identifiers

UNII
E4GA8884NN
CAS number
7664-38-2
InChI Key
NBIIXXVUZAFLBC-UHFFFAOYSA-N
InChI
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
IUPAC Name
phosphoric acid
SMILES
OP(O)(O)=O

References

General References
  1. Pubchem [Link]
  2. ChemIDplus [Link]
  3. inChem [Link]
Human Metabolome Database
HMDB0002142
KEGG Compound
C00009
PubChem Compound
1004
PubChem Substance
347827839
ChemSpider
979
BindingDB
14671
RxNav
8259
ChEBI
26078
ChEMBL
CHEMBL1187
Wikipedia
Phosphoric_acid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2Active Not RecruitingTreatmentMyelodysplastic Syndrome1
1, 2Unknown StatusTreatmentPancreatic Neoplasms1
Not AvailableCompletedTreatmentSelective Enamel Etching in Dental Restorations1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidOral
LiquidDental
SolutionOral
Injection, solutionIntravenous
GelDental
SolutionIntravenous
SolutionOral750 mg/1
GelTopical
LiquidDental; Topical
LiquidTopical
InjectionIntravenous
InjectionIntravenous0.21 g/100ml
SolutionParenteral
PasteDental
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1Chemaxon
pKa (Strongest Acidic)1.8Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area77.76 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity14.65 m3·mol-1Chemaxon
Polarizability5.81 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0002-0794000000-6c866e626b9356994d46
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0002-9000000000-1805c2208b5ff15a75b1
GC-MS Spectrum - EI-BGC-MSsplash10-0002-0394000000-3a469377821d88bd699f
GC-MS Spectrum - GC-MSGC-MSsplash10-0002-0794000000-6c866e626b9356994d46
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-000t-0972000000-2ddd7182426dbace5342
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-000t-9000000000-0e85f764ac98e8949759
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-001i-9000000000-869a362083996a0cec77
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-03di-9000000000-801101cccfd6c25271d4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-e1407864f105de66a2f9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-db2139553961b678b485
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004j-9000000000-961fe4d1496e303f97f0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-9000000000-416aebf307f73f4abc59
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-809431ded7e758382c4f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001j-9000000000-98ed77d983462bd30208
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-105.4215532
predicted
DarkChem Lite v0.1.0
[M-H]-117.37956
predicted
DeepCCS 1.0 (2019)
[M+H]+120.046234
predicted
DeepCCS 1.0 (2019)
[M+Na]+128.26027
predicted
DeepCCS 1.0 (2019)

Drug created at November 30, 2015 19:10 / Updated at January 09, 2021 18:40